1. Prevention of atheroma formation in arteries
2. Prevention of erosion or rupture of atheromatous plaques in the coronary arteries and cerebral circulation
3. Clot-dissolving drugs (thrombolytic agents)
4. Agents that prevent clot formation (anticoagulants and antiplatelet drugs).

Страницы: 1 | 2

• I. CAUSES OF BLOOD CLOTS
  Blood clots are believed to occur in the coronary arteries because of platelets that become sticky when they come in contact with the damaged lining of blood vessels, where atheroma formation has commenced. Platelets interact with the damaged surfaces, and chemicals that are produced at the site cause the platelets to clump (platelet aggregation) and form a clot. Chemicals in the body that cause platelets to clump or sludge include collagen from the damaged vessel wall, adrenaline, and a very powerful platelet-clumping chemical called thromboxane A2.
• II. NONDRUG TREATMENT
  As a nondrug treatment, these dietary measures are strongly advised. Eat less fatty meals, which reduces saturated fat and hydrogenated fat intake. Saturated fats form LDL (bad) cholesterol in the body. Try to increase the intake of foods that may prevent blood clotting, particularly onions, garlic, and foods containing alpha-linolenic and eicosapentaenoic acids; the latter are derived from fish and cod liver oil. The polyunsaturated acids in the diet of the fish-eating Japanese and Inuit prevent clumping of platelets and have favorable effects on the blood-clotting system. These foods decrease platelet clump¬ing as well as increase vessel wall prostacyclin (prostaglan-din), a compound that helps to keep the lining of the artery clean. Try to increase your consumption of fish, for example, mackerel and salmon, which have a high content of the polyunsaturated fatty acids. Linolenic acid has been proven valuable in the prevention of plaque (see Section VII in the chapter Cholesterol).
• III. DRUG TREATMENT A. Thrombolytic Agents
  Rentrop reported successful recanalization of coronary thrombotic occlusion with intracoronary infusion of strep-tokinase in patients. Streptokinase was the first throm-bolytic agent employed, and its usefulness was first documented in the Italian trial of intravenous streptoki-nase (GISSI). This drug remains in use today because it is the least expensive of the available thrombolytic agents and has a low risk for intracranial hemorrhage compared with other agents that are modestly better in dissolving clots. The internationally run British trial, the International Study of Infarct Survival (ISIS–2), showed that an intravenous infusion of 1.5 million units of streptokinase administered over 1 h is not particularly expensive or troublesome to give routinely, and it provides significant reduction in mortality and morbidity in patients seen within 3 hof onset of chest pain. Most important, intra¬venous or subcutaneous heparin is not necessary when streptokinase is used; this reduces the risk for intracranial hemorrhage.
• BIBLIOGRAPHY
  Abrams, J., Frishman, W. H., Bates, S. M. et al. Pharmacologic options